Innovations in Myeloma Therapies: Promise of ADCs, CELMoDs, BCL2 Inhibitors, & SINEs | Dan Vogl, MD

At the HealthTree Roundtable in Philadelphia, Dr. Dan Vogl, MD, explores the rapidly expanding world of multiple myeloma treatment options. In this insightful session, he discusses how emerging therapies—Antibody Drug Conjugates (ADCs), CELMoDs, BCL2 inhibitors, and SINEs—are transforming care for myeloma patients and offering more personalized, effective approaches.

Learn how these novel drug classes work, which patient groups may benefit most, and what clinical trials are teaching us about their potential.